Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial - Poll - MDSpire

Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial

  • By

  • Matthias Augustin

  • Steven R. Feldman

  • Richard B. Warren

  • April Armstrong

  • Ronald Vender

  • Anna López-Ferrer

  • William H. Dawe

  • Jérémy Lambert

  • Balint Szilagyi

  • Bengt Hoepken

  • Rhys Warham

  • Alice B. Gottlieb

  • April 1, 2026

  • 0 min

Share

Original Source(s)

Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial

  • by Matthias Augustin, Steven R. Feldman, Richard B. Warren, April Armstrong, Ronald Vender, Anna López-Ferrer, William H. Dawe, Jérémy Lambert, Balint Szilagyi, Bengt Hoepken, Rhys Warham, Alice B. Gottlieb

  • April 1, 2026

Related Content

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.